Osiris Therapeutics
Mar 14, 2019
BioNTech lines up $800M; Deerfield remunerates; Britain’s Smith & Nephew to acquire Osiris
BioNTech lines up USD 800 Million for fuelling mRNA R&D BioNTech is lining up a Nasdaq IPO that raises USD 800 million. The German mRNA specialist is contemplating to stimulate its cash-intensive plans. BioNTech has booked Bank of America and JPMorgan with a plan to list on Nasdaq. The current plan is to inc...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
